ERYP.PA - ERYTECH Pharma S.A.

Paris - Paris Delayed Price. Currency in EUR

ERYTECH Pharma S.A.

Bâtiment Adénine
60 Avenue Rockefeller
Lyon 69008
France
33 4 78 74 44 38
http://erytech.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees172

Key Executives

NameTitlePayExercisedYear Born
Mr. Gil Beyen BVBAChairman & CEO449.66kN/A1962
Mr. Jérôme Bailly Pharm.D.VP, Director of Pharmaceutical Operations & Deputy GM223.14kN/A1979
Mr. Eric Soyer Ph.D.CFO & COON/AN/A1966
Dr. Alexander ScheerChief Scientific OfficerN/AN/A1962
Naomi EichenbaumDirector Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.

Corporate Governance

ERYTECH Pharma S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.